COMMUNIQUÉS West-GlobeNewswire
-
Disclosure of voting rights at AGM in Vistin Pharma ASA
20/05/2026 -
CorVel Announces Revenues and Earnings
20/05/2026 -
Avricore Health Announces $1.25 Million Financing
20/05/2026 -
Winner Medical Breaks Ground on New Production Base in Vietnam to Serve Global Medical Supply Chains Through Local Manufacturing
20/05/2026 -
Largest-ever Canadian clinical trial tests “poop pills” to improve immunotherapy for lung cancer
20/05/2026 -
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
20/05/2026 -
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
20/05/2026 -
Un essai clinique canadien sans précédent évalue des « comprimés de selles » pour améliorer l’immunothérapie du cancer du poumon
20/05/2026 -
Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder
20/05/2026 -
IBA launches Rhodotron® LITE, a new low‑power X‑ray accelerator expanding access to sustainable irradiation solutions
20/05/2026 -
IBA lance Rhodotron® LITE, un nouvel accélérateur à rayons X de faible puissance qui facilite l’accès à des solutions d’irradiation durables
20/05/2026 -
SERB Pharmaceuticals acquiert auprès de Hansa Biopharma les droits européens et MENA d’Idefirix® (imlifidase) pour 115 millions d’euros
20/05/2026 -
Java Tide Critical Assessment: The Gelatin Ice Trick Before Bed Using the Java Tide Formula Recipe
20/05/2026 -
Shiny Smile Veneers Claims Evaluated (2026 Consumer Report Update) Critical Complaints Investigated
20/05/2026 -
SlimTide Claims Evaluated: The Baking Soda Water Shot Gelatin Trick for Losing Weight Naturally by Slim Tide
20/05/2026 -
Ozari Health Launches Nationwide Telehealth Platform for Compounded Semaglutide and Tirzepatide Starting at $86 Per Month
19/05/2026 -
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
19/05/2026 -
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
19/05/2026 -
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
19/05/2026
Pages